BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Table 1 Clinical characteristics of HN1 L expression in patients from Sun Yat-sen University Cancer Center cohort, n (%)/mean ± SD/median (min-max)

HN1 L-low (n = 42)
HN1 L-high (n = 42)
P value
Age
54.4 ± 9.2252.0 ± 13.00.34
55.0 (34.0-75.0)51.5 (25.0-77.0)
Sex
Female15 (35.7)19 (45.2)0.505
Male27 (64.3)23 (54.8)
BMI
22.5 ± 3.5822.1 ± 2.990.524
22.2 (15.4-30.9)21.7 (16.8-28.9)
MMR status
dMMR5 (11.9)3 (7.1)0.909
pMMR26 (61.9)23 (54.8)
Missing11 (26.2)16 (38.1)
OS outcome
Alive40 (95.2)38 (90.5)0.672
Dead2 (4.8)4 (9.5)
OS follow-up time
62.4 ± 18.154.6 ± 26.10.116
63.8 (32.6-98.4)51.1 (12.6-100)
DFS outcome
Disease-free34 (81.0)36 (85.7)0.77
Recurrence or death8 (19.0)6 (14.3)
DFS follow-up time
57.1 ± 21.452.0 ± 26.70.34
56.2 (13.7-98.4)48.4 (5.10-100)
TNM stage
I4 (9.5)3 (7.1)0.923
II30 (71.4)31 (73.8)
III8 (19.0)8 (19.0)
CEA
22.0 ± 1097.27 ± 10.60.388
2.98 (0.231-708)2.85 (0.460-55.4)
CA19-9
57.6 ± 12582.4 ± 2840.607
15.6 (0.600-592)16.0 (0.600-1820)
Chemotherapy
No17 (40.5)14 (33.3)0.651
Yes25 (59.5)28 (66.7)
Table 2 Univariate Cox regression analyses for overall survival
Variables
HR (95%CI)
P value
Age1.03 (0.94-1.13)0.45
Sex3.06 (0.34-27.44)0.31
BMI0.82 (0.61-1.10)0.19
CEA0.99 (0.98-1.01)0.87
CA19-90.99 (0.99-1.00)0.96
HN1 L group7.22 (0.82-63.2)0.07


Write to the Help Desk